Showing results (61-70 of 115) with videos related to
Sort By:
Pageof 12
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 1, 1995
Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipientsT van Gelder, A H Mulder, A H Balk, et al.Transplant International : Official Journal of the European Society for Organ Transplantation|July 17, 1998
The TNF-alpha system after successful living-related kidney transplantationI C van Riemsdijk-van Overbeeke, C C Baan, E H Loonen, et al.Expert Opinion on Drug Metabolism & Toxicology|March 25, 2016
Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerationsJ T Tang, L M Andrews, T van Gelder, et al.Transplantation|August 15, 2001
Proteinuria after renal transplantation affects not only graft survival but also patient survivalJ I Roodnat, P G Mulder, J Rischen-Vos, et al.Transplant International : Official Journal of the European Society for Organ Transplantation|July 17, 1998
Donor-specific CTL frequencies in peripheral blood in relation to graft vascular disease after clinical heart transplantationN M van Besouw, C R Daane, P de Kuiper, et al.Clinical Transplantation|February 29, 2000
A longitudinal study of TGF-beta1 protein levels in renal allograft recipients converted from CsA to MMF or AZAB J van der Mast, N M van Besouw, P de Kuiper, et al.Immunopharmacology|September 1, 1995
Pharmacodynamics of prophylactic antirejection therapy with an anti interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantationC J Hesse, T van Gelder, L M Vaessen, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 1995
Dopamine-producing paraganglioma not visualized by iodine-123-MIBG scintigraphyT van Gelder, G T Verhoeven, P de Jong, et al.Transplantation|July 15, 1996
A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantationT van Gelder, A H Balk, F A Jonkman, et al.Clinical Pharmacology and Therapeutics|February 22, 2008
Renal function as a predictor of irinotecan-induced neutropeniaF A de Jong, J M van der Bol, R H J Mathijssen, et al.Pageof 12